Skip to content

Study · Animal study (in vivo) · 2006

3 results

Role of hypothalamic interleukin-1beta (IL-1beta) in regulation of energy homeostasis by melanocortins.

Wisse BE, Ogimoto K, Schwartz MW

Peptides7 Nov 2005Cited by 23 (Europe PMC)

PMID16274848 (opens in a new tab)DOI10.1016/j.peptides.2005.08.020 (opens in a new tab)PepBankPUB-16274848
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    The melanocortin agonist MTII increased hypothalamic IL-1beta mRNA levels two-fold.

    In plain wordsIn animals, the melanocortin drug MTII raised the message for the inflammation signal IL-1beta in the hypothalamus two-fold.

    Peptide
    Melanotan II
    Outcome
    IncreaseHypothalamic IL-1beta mRNA
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A melanocortin agonist, MTII, increased hypothalamic IL-1beta mRNA levels by two-fold

Studies that did not test the peptide alone2

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 02AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    Pharmacological or genetic disruption of IL-1 receptor signaling prevented the MTII-mediated reduction in locomotor activity.

    In plain wordsIn animals, blocking IL-1 receptor signaling prevented the drop in movement that MTII caused.

    Peptide
    Melanotan II
    Outcome
    IncreaseMTII-mediated reduction in locomotor activity with IL-1 receptor disruption
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Metabolic and weight

    Source sentences

    Summary
    Pharmacological or genetic disruption of IL-1 receptor signaling prevented MTII-mediated reductions in locomotor activity

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  2. 03AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    Disruption of IL-1 receptor signaling did not reduce MTII-induced anorexia.

    In plain wordsIn animals, blocking IL-1 receptor signaling did not lessen the loss of appetite that MTII caused.

    Peptide
    Melanotan II
    Outcome
    No significant changeMTII-induced anorexia with IL-1 receptor disruption
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    but did not reduce MTII-induced anorexia.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.